The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies

MS Freedman, JS Wolinsky, G Comi, L Kappos, TP Olsson, AE Miller, K Thangavelu, M Benamor, P Truffinet, PW O'Connor, TEMSO Study Group, TOWER Study Group

Research output: Contribution to journalArticle

Abstract

Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the phase 3, pooled TEMSO (NCT00134563) and TOWER (NCT00751881) dataset is to evaluate the effect of teriflunomide treatment on annualised relapse rate and disability worsening across patient subgroups defined according to prior disease-modifying therapy exposure. This analysis provides further supportive evidence for a consistent effect of teriflunomide across a broad range of patients with relapsing MS, including patients who have used and discontinued other disease-modifying therapies.
Original languageEnglish
Pages (from-to)535-539
Number of pages5
JournalMultiple Sclerosis
Volume24
Issue number4
DOIs
Publication statusPublished - 2018

Fingerprint Dive into the research topics of 'The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies'. Together they form a unique fingerprint.

  • Cite this

    Freedman, MS., Wolinsky, JS., Comi, G., Kappos, L., Olsson, TP., Miller, AE., Thangavelu, K., Benamor, M., Truffinet, P., O'Connor, PW., Study Group, TEMSO., & Group, TOWER. S. (2018). The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. Multiple Sclerosis, 24(4), 535-539. https://doi.org/10.1177/1352458517695468